Opendata, web and dolomites


Saving millions of lives by enabling an effective treatment for Heart Failure patients; V-LAP, a revolutionary, miniaturized implant and its dedicated wearable device.

Total Cost €


EC-Contrib. €






 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

ineffective    fluids    minimally    pressure    earliest    diabetes    weeks    aged    indicator    trials    unable    sudden    plan    data    blood    company    people    patient    mobile    monitor    synchronize    day    least    lap    leg    causes    30    levels    color    vectorious    inductive    belt    65    excess    clinicians    powered    min    total    medications    quality    measured    hf    catheter    prescription    collected    filling    chronic    decreasing    expenditure    events    invasively    portfolio    device    organs    global    symptoms    outcome    edema    predict    28    invasive    miniaturized    red    hospital    patients    98    glucose    daily    provider    back    12    transition    detecting    tiredness    hemodynamic    sent    efficacy    adhf    coupling    flow    covered    meet    patents    lv    heart    battery    adjust       disruptive    body    public    mortality    worsening    yellow    industrialization    hospitalization    external    healthcare    clinical    life    threatening    code    dyspnea    ventricular    worn    promptly    green    implantable    ing    completely    decompensate    acute    takes    trough    left    clothes    pump    swelling    nhs    ac    worldwide    website    free    procedure   

Project "V-LAP" data sheet

The following table provides information about the project.


Organization address
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed trough a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/ red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes. During Phase 1 project the Company will assess scale-up industrialization plan, product development and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

oWBI (2018)

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Read More  

Aerial BCP (2017)

A 1Gpixel Camera to Open the Markets of Aerial Data Acquisition

Read More